ClinicalTrials.gg
CompletedNCT04642079Updated Jan 22, 2024Results posted

Safety and Immunogenicity Study of 20vPnC in Healthy Children 15 Months Through 17 Years of Age

A Phase 3 interventional study of 20vPnC in Pneumococcal Disease, sponsored by Pfizer. Completed at 43 sites in United States. Open to participants aged 15 Months to 17 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2024-01-22.

Sponsored by Pfizer · Phase 3, Interventional, and Prevention

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 3
Study type
Interventional
Enrollment
839
Allocation
Non-randomized
Ages
15 Months to 17 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 19 studies testing Pneumococcal 20-Valent Conjugate Vaccine in Pneumococcal Infections — 2 open to participants now, 3 under way, 1 of them phase 3. Pneumococcal 20-Valent Conjugate Vaccine · Pneumococcal Infections.

Enrollment
9th of 19
839 · median 668
Started
2020
with 4 others
Phase 3
14 of 19
1 open now
Registered
8th of 19
by date
Lead sponsor
16 of 19
Pfizer

Among the 19 studies testing Pneumococcal 20-Valent Conjugate Vaccine in Pneumococcal Infections, this one is the 9th largest by enrollment, is one of 5 that started in 2020, is one of 14 in phase 3, and was the 8th registered.

Pneumococcal Infections

299 studies on the registry are indexed under Pneumococcal Infections; 26 are open to participants now.

Browse Pneumococcal Infections studies →

Open to participants now

2 of the 19 studies testing Pneumococcal 20-Valent Conjugate Vaccine in Pneumococcal Infections are open now, in 2 countries. Recruiting first, the newest first:

By country, each count listing its studies:

All 2 open studies →

About Pneumococcal 20-Valent Conjugate Vaccine

Pneumococcal 20-Valent Conjugate Vaccine: first FDA approval 2021 (Prevnar 20). What it is approved for, and how studies give it, is on its page →

Who these studies take

Of the 20 Pneumococcal Infections studies recruiting now, 4 (20%) set no upper age limit and 14 (70%) stop at 75 or younger; 14 take children under 18; 16 take healthy volunteers.

This study: 15 Months to 17 Years · all sexes · healthy volunteers too.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 19 studies testing Pneumococcal 20-Valent Conjugate Vaccine in Pneumococcal Infections, or all of them as a file.
02

Study summary

This study is designed to evaluate the safety and immunogenicity of 20vPnC in healthy children 15 months through 17 years of age

03

Conditions studied

  • Pneumococcal Disease
04

Who can participate

Ages eligible
15 Months to 17 Years
Sexes eligible
All
Accepts healthy volunteers
Yes

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Male or female children ≥15 months to \<18 years of age at the time of consent.
  • Healthy children determined by clinical assessment, including medical history and clinical judgment, to be eligible for the study.
  • For children \<5 years of age, written documentation of receipt of at least 3 doses of 13vPnC. The last dose of 13vPnC must have been administered >2 months before enrolment into the study

Exclusion criteria

Exclusion Criteria:

  • History of severe adverse reaction associated with a vaccine and/or severe allergic reaction (eg, anaphylaxis)
  • Major known congenital malformation or serious chronic disorder
  • Other acute or chronic medical or psychiatric condition or laboratory abnormality that may increase the risk associated with study participation or product administration or may interfere with the interpretation of study results
  • Previous vaccination with any investigational pneumococcal vaccine or with PPSV23, or planned receipt through study participation
  • Cohorts 3 and 4: Pregnant or breastfeeding female participants
Terms in these criteria, in plain language(1)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

05

Study design

Phase
Phase 3
Primary purpose
Prevention
Allocation
Non-randomized
Intervention model
Single group
Masking
None (open label)
Enrollment
839 participants (actual)

Study arms

  • Experimental
    Cohort 1: =>15 through 23 months of age

    20vPnC

    Biological: 20vPnC

  • Experimental
    Cohort 2: 2 through 4 years of age

    20vPnC

    Biological: 20vPnC

  • Experimental
    Cohort 3: 5 through 9 years of age

    20vPnC

    Biological: 20vPnC

  • Experimental
    Cohort 4: 10 through 17 years of age

    20vPnC

    Biological: 20vPnC

Interventions

  • Biological20vPnC

    20-valent pneumococcal conjugate vaccine

06

What researchers measure

Primary outcomes

  1. Percentage of Participants Reporting Prompted Local Reactions Within 7 Days After Vaccination

    Local reactions included redness, swelling and, pain at the injection site, recorded by parent's/legal guardians of participants in an electronic diary (e-diary). Redness and swelling were measured and recorded in measuring device units. One measuring device unit =0.5 centimeter (cm). Redness and swelling were graded as mild: \> 0.0 to 2.0 cm, moderate: \>2.0 to 7.0 cm and severe: \>7.0 cm. Pain at the injection site was graded as mild: hurt if gently touched (cohort 1) and did not interfere with activity (cohort 2-4); moderate: hurt if gently touched with crying (cohort 1) and interfered with daily activity (cohort 2-4) and; severe: limited limb movement (cohort 1) and prevented daily activity (cohort 2-4). 95 percent (%) confidence interval (CI) was based on Clopper and Pearson method.

    Time frame: Within 7 days after vaccination on Day 1

  2. Percentage of Participants Reporting Prompted Systemic Events Within 7 Days After Vaccination: Cohort 1

    Systemic events for Cohort 1 included fever, decreased appetite, drowsiness/increased sleep and irritability, recorded by parents/legal guardians of participant's using an e-diary. Fever was defined as temperature \>=38.0 degrees Celsius (C) and categorized as \>=38.0 to 38.4 degrees C, \>38.4 to 38.9 degrees C, \>38.9 to 40.0 degrees C and \>40.0-degrees C. Decreased appetite was graded as mild (decreased interest in eating), moderate (decreased oral intake) and severe (refusal to feed). Drowsiness was graded as mild (increased or prolonged sleeping bouts), moderate (slightly subdued, interfered with daily activity) and severe (disabling, not interested in usual daily activity). Irritability: graded as mild (easily consolable), moderate (required increased attention) and severe (inconsolable, crying could not be comforted). 95% CI was based on Clopper and Pearson method.

    Time frame: Within 7 days after vaccination on Day 1

  3. Percentage of Participants Reporting Prompted Systemic Events Within 7 Days After Vaccination: Cohorts 2, 3 and 4

    Systemic events for Cohort 2-4 included fever, fatigue, headache, muscle pain and joint pain, recorded by parents/legal guardians of participant's using an e-diary. Fever was defined as temperature \>=38.0 degrees C and categorized as \>=38.0 to 38.4 degrees C, \>38.4 to 38.9 degrees C, \>38.9 to 40.0 degrees C and \>40.0 degrees C. Fatigue, headache, muscle pain and joint pain were graded as mild (no interference with activity), moderate (some interference with activity) and severe (prevents daily routine activity). 95% CI was based on Clopper and Pearson method.

    Time frame: Within 7 days after vaccination on Day 1

  4. Percentage of Participants Reporting Adverse Events (AEs) up to 1 Month After Vaccination

    An AE was any untoward medical occurrence in a participant, temporally associated with the use of study treatment, whether or not considered related to the study treatment. 95% CI was based on the Clopper and Pearson method. Only AEs collected by non-systematic assessment (i.e. excluding local reactions and systemic events) were reported in this outcome measure.

    Time frame: From vaccination (on Day 1) up to 1 month after vaccination

  5. Percentage of Participants Reporting Serious Adverse Events (SAEs) up to 6 Months After Vaccination

    An SAE was any untoward medical occurrence that occurred, at any dose: resulted in death; required inpatient hospitalization or prolongation of existing hospitalization; was life-threatening; resulted in persistent or significant disability/ incapacity; was a congenital anomaly/birth defect and other important medical events. 95% CI was based on the Clopper and Pearson method.

    Time frame: From vaccination (on Day 1) up to 6 months after vaccination

  6. Percentage of Participants Reporting Newly Diagnosed Chronic Medical Conditions (NDCMCs) up to 6 Months After Vaccination

    An NDCMC was defined as a disease or medical condition, not previously identified, that was expected to be persistent or was otherwise long-lasting in its effects. 95% CI was based on the Clopper and Pearson method.

    Time frame: From vaccination (on Day 1) up to 6 months after vaccination

  7. Geometric Mean Fold Rises (GMFRs) of Pneumococcal Serotype-Specific Immunoglobulin G (IgG) Concentrations for the 7 Additional Serotypes From Before to 1 Month After 20vPnC Vaccination: Cohort 1 and 2

    Pneumococcal serotype-specific IgG concentrations were measured from serum samples for the 7 additional 20vPnC serotypes: 8, 10A, 11A, 12F, 15B, 22F and 33F. GMFR = geometric mean of fold rise from before vaccination on Day 1 to 1 month after vaccination with 20vPnC. GMFRs and corresponding 2-sided 95% CIs were calculated by exponentiating the mean logarithm of fold rises and the corresponding 2-sided 95% CIs (based on Student's t distribution). Superiority of IgG concentration 1 month after 20vPnC to before vaccination for each serotype was demonstrated if the 95% lower CI of GMFR was \>1.

    Time frame: Before vaccination on Day 1 to 1 month after vaccination

  8. GMFRs of Pneumococcal Serotype-Specific Opsonophagocytic Activity (OPA) Titers for the 7 Additional Serotypes From Before to 1 Month After 20vPnC Vaccination: Cohort 3 and 4

    Pneumococcal serotype-specific OPA titers were measured from serum samples for 7 the additional 20vPnC serotypes: 8, 10A, 11A, 12F, 15B, 22F and 33F. GMFR = geometric mean of fold rise from before vaccination on Day 1 to 1 month after vaccination with 20vPnC. GMFRs and the corresponding 2-sided 95% CIs were calculated by exponentiating the mean logarithm of fold rises and the corresponding 2-sided 95% CIs (based on the Student's t distribution). Superiority of OPA titers 1 month after 20vPnC to before vaccination for each serotype was demonstrated if the 95% lower CI of the GMFR was \>1.

    Time frame: Before vaccination on Day 1 to 1 month after vaccination

Secondary outcomes

  1. Percentage of Participants With Predefined Levels of Pneumococcal Serotype-Specific IgG Concentrations for the 7 Additional Serotypes at 1 Month After Vaccination in Cohort 1 Only

    Pneumococcal serotype-specific IgG concentrations were measured from serum samples for the 7 additional 20vPnC serotypes: 8, 10A, 11A, 12F, 15B, 22F and 33F. Percentage of participants with predefined level (\>=0.35 micrograms per milliliter) of IgG concentration for the 7 additional 20vPnC serotypes was presented. 2-sided 95% CI was based on Clopper and Pearson method.

    Time frame: At 1 Month after vaccination on Day 1

  2. Percentage of Participants With >=4-fold Rise in Pneumococcal Serotype-Specific OPA Titers for the 7 Additional Serotypes From Before to 1 Month After Vaccination: Cohorts 2, 3, and 4 Only

    Pneumococcal serotype-specific OPA titers were measured from serum samples for 7 additional 20vPnC serotypes: 8, 10A, 11A, 12F, 15B, 22F and 33F. Percentage of participants with \>=4-fold rise in serotype-specific OPA titers from before vaccination to 1 month after vaccination with 20vPnC and the associated 2-sided 95% CI based on the Clopper and Pearson method was presented. OPA titers were measured in a randomized subset of samples in Cohort 2 for this outcome measure.

    Time frame: Before vaccination on Day 1 to 1 month after vaccination

  3. Geometric Mean Concentrations (GMCs) of Pneumococcal Serotype-Specific IgG for the 20vPnC Serotypes Before and 1 Month After Vaccination

    Pneumococcal serotype-specific IgG concentrations were measured for serum samples for 13vPnC serotypes: 1, 3, 4, 5, 6A, 6B, 7F, 9V, 14, 18C, 19A, 19F, and 23F; and 7 additional 20vPnC serotypes: 8, 10A, 11A, 12F, 15B, 22F and 33F. GMCs the corresponding 2-sided 95% CIs were calculated by exponentiating the mean logarithm of the concentrations and the corresponding 2-sided 95% CIs (based on the Student's t distribution).

    Time frame: Before vaccination and 1 month after vaccination

  4. GMFRs of Pneumococcal Serotype-Specific IgG Concentrations for the 13vPnC Serotypes From Before to 1 Month After Vaccination: Cohort 1 and 2

    Pneumococcal serotype-specific IgG concentrations were measured from serum samples for 13vPnC serotypes: 1, 3, 4, 5, 6A, 6B, 7F, 9V, 14, 18C, 19A, 19F and 23F. GMFR = geometric mean of fold rise from before vaccination on Day 1 to 1 month after vaccination with 20vPnC. GMFRs and the corresponding 2-sided 95% CIs were calculated by exponentiating the mean logarithm of the fold rises and the corresponding 2-sided 95% CIs (based on the Student's t distribution).

    Time frame: Before vaccination on Day 1 to 1 month after vaccination

  5. GMFRs of Pneumococcal Serotype-Specific IgG Concentrations for the 20vPnC Serotypes From Before to 1 Month After Vaccination: Cohort 3 and 4

    Pneumococcal serotype-specific IgG concentrations were measured from serum samples for 13vPnC serotypes: 1, 3, 4, 5, 6A, 6B, 7F, 9V, 14, 18C, 19A, 19F and 23F; and 7 additional 20vPnC serotypes: 8, 10A, 11A, 12F, 15B, 22F and 33F. GMFR = geometric mean of fold rise from before vaccination on Day 1 to 1 month after vaccination with 20vPnC. GMFRs and the corresponding 2-sided 95% CIs were calculated by exponentiating the mean logarithm of the fold rises and the corresponding 2-sided 95% CIs (based on the Student's t distribution).

    Time frame: Before vaccination on Day 1 to 1 month after vaccination

  6. Geometric Mean Titers (GMTs) of Pneumococcal Serotype-Specific OPA Titers for the 20vPnC Serotypes Before and 1 Month After Vaccination

    Pneumococcal serotype-specific OPA titers were measured from serum samples for 13vPnC serotypes: 1, 3, 4, 5, 6A, 6B, 7F, 9V, 14, 18C, 19A, 19F, and 23F; and 7 additional 20vPnC serotypes: 8, 10A, 11A, 12F, 15B, 22F and 33F. GMTs and 2-sided 95% CIs were calculated by exponentiating the mean logarithm of the titers and the corresponding 2-sided 95% CIs (based on the Student's t distribution). OPA titers were measured in a randomized subset of serum samples in Cohorts 1 and 2. OPA titers for the 13vPnC serotypes were measured in a randomized subset of serum samples in Cohorts 3 and 4.

    Time frame: Before vaccination on Day 1 and 1 month after vaccination

  7. GMFRs of Pneumococcal Serotype-Specific OPA Titers for the 20vPnC Serotypes From Before to 1 Month After Vaccination: Cohorts 1 and 2

    Pneumococcal serotype-specific OPA titers were measured from serum samples for 13vPnC serotypes: 1, 3, 4, 5, 6A, 6B, 7F, 9V, 14, 18C, 19A, 19F, and 23F; and 7 additional 20vPnC serotypes: 8, 10A, 11A, 12F, 15B, 22F and 33F. GMFR = geometric mean of fold rise from before vaccination on Day 1 to 1 month after vaccination with 20vPnC. GMFRs and the corresponding 2-sided 95% CIs were calculated by exponentiating the mean logarithm of the fold rises and the corresponding 2-sided 95% CIs (based on the Student's t distribution). OPA titers measured in a randomized subset of serum samples in Cohorts 1 and 2 for this outcome measure.

    Time frame: Before vaccination on Day 1 to 1 month after vaccination

  8. GMFRs of Pneumococcal Serotype-Specific OPA Titers for the 13vPnC Serotypes From Before to 1 Month After Vaccination: Cohorts 3 and 4

    Pneumococcal serotype-specific OPA titers were measured for 13vPnC serotypes: 1, 3, 4, 5, 6A, 6B, 7F, 9V, 14, 18C, 19A, 19F, and 23F. GMFR = geometric mean of fold rise from before vaccination on Day 1 to 1 month after vaccination with 20vPnC. GMFRs and the corresponding 2-sided 95% CIs were calculated by exponentiating the mean logarithm of the fold rises and the corresponding 2-sided 95% CIs (based on the Student's t distribution). OPA titers for the 13vPnC serotypes were measured in a randomized subset of serum samples in Cohorts 3 and 4.

    Time frame: Before vaccination on Day 1 to 1 month after vaccination

07

Results

Posted Apr 26, 2023

Participant flow

Participant flow — Overall Study
MilestoneCohort 1: 20vPnC: >=15 to <24 MonthsCohort 2: 20vPnC: >=2 to <5 YearsCohort 3: 20vPnC: >=5 to <10 YearsCohort 4: 20vPnC: >=10 to <18 Years
Started210219203207
Vaccinated209216201205
Completed207210199203
Not completed3944
Withdrew: Lost to follow-up2520
Withdrew: Withdrawal by subject0412
Withdrew: Other0001
Withdrew: No longer met eligibility criteria1011

Outcome measures

PrimaryPercentage of Participants Reporting Prompted Local Reactions Within 7 Days After Vaccination

Local reactions included redness, swelling and, pain at the injection site, recorded by parent's/legal guardians of participants in an electronic diary (e-diary). Redness and swelling were measured and recorded in measuring device units. One measuring device unit =0.5 centimeter (cm). Redness and swelling were graded as mild: \> 0.0 to 2.0 cm, moderate: \>2.0 to 7.0 cm and severe: \>7.0 cm. Pain at the injection site was graded as mild: hurt if gently touched (cohort 1) and did not interfere with activity (cohort 2-4); moderate: hurt if gently touched with crying (cohort 1) and interfered with daily activity (cohort 2-4) and; severe: limited limb movement (cohort 1) and prevented daily activity (cohort 2-4). 95 percent (%) confidence interval (CI) was based on Clopper and Pearson method.

Time frame:
Within 7 days after vaccination on Day 1
Reported as:
Number · Percentage of participants
Percentage of Participants Reporting Prompted Local Reactions Within 7 Days After Vaccination
Percentage of participantsCohort 1: 20vPnC: >=15 to <24 MonthsCohort 2: 20vPnC: >=2 to <5 YearsCohort 3: 20vPnC: >=5 to <10 YearsCohort 4: 20vPnC: >=10 to <18 Years
Redness: Any37.7 (31.1 to 44.8)39.1 (32.5 to 45.9)37.2 (30.5 to 44.3)15.1 (10.5 to 20.8)
Redness: Mild30.4 (24.2 to 37.2)22.8 (17.4 to 29.0)16.6 (11.7 to 22.5)10.7 (6.8 to 15.8)
Redness: Moderate7.4 (4.2 to 11.8)15.3 (10.8 to 20.9)18.6 (13.4 to 24.7)3.9 (1.7 to 7.5)
Redness: Severe0 (0.0 to 1.8)0.9 (0.1 to 3.3)2.0 (0.6 to 5.1)0.5 (0.0 to 2.7)
Swelling: Any22.1 (16.6 to 28.4)23.3 (17.8 to 29.5)27.1 (21.1 to 33.9)15.6 (10.9 to 21.3)
Swelling: Mild15.7 (11.0 to 21.4)11.6 (7.7 to 16.7)10.6 (6.7 to 15.7)5.4 (2.7 to 9.4)
Swelling: Moderate6.4 (3.4 to 10.7)11.2 (7.3 to 16.2)15.6 (10.8 to 21.4)10.2 (6.5 to 15.2)
Swelling: Severe0 (0.0 to 1.8)0.5 (0.0 to 2.6)1.0 (0.1 to 3.6)0 (0.0 to 1.8)
Pain at the injection site: Any52.5 (45.4 to 59.5)66.0 (59.3 to 72.3)82.9 (77.0 to 87.9)82.0 (76.0 to 87.0)
Pain at the injection site: Mild41.7 (34.8 to 48.8)47.0 (40.2 to 53.9)56.8 (49.6 to 63.8)62.9 (55.9 to 69.6)
Pain at the injection site: Moderate9.8 (6.1 to 14.7)17.7 (12.8 to 23.4)24.6 (18.8 to 31.2)17.6 (12.6 to 23.5)
Pain at the injection site: Severe1.0 (0.1 to 3.5)1.4 (0.3 to 4.0)1.5 (0.3 to 4.3)1.5 (0.3 to 4.2)
PrimaryPercentage of Participants Reporting Prompted Systemic Events Within 7 Days After Vaccination: Cohort 1

Systemic events for Cohort 1 included fever, decreased appetite, drowsiness/increased sleep and irritability, recorded by parents/legal guardians of participant's using an e-diary. Fever was defined as temperature \>=38.0 degrees Celsius (C) and categorized as \>=38.0 to 38.4 degrees C, \>38.4 to 38.9 degrees C, \>38.9 to 40.0 degrees C and \>40.0-degrees C. Decreased appetite was graded as mild (decreased interest in eating), moderate (decreased oral intake) and severe (refusal to feed). Drowsiness was graded as mild (increased or prolonged sleeping bouts), moderate (slightly subdued, interfered with daily activity) and severe (disabling, not interested in usual daily activity). Irritability: graded as mild (easily consolable), moderate (required increased attention) and severe (inconsolable, crying could not be comforted). 95% CI was based on Clopper and Pearson method.

Time frame:
Within 7 days after vaccination on Day 1
Reported as:
Number · Percentage of participants
Percentage of Participants Reporting Prompted Systemic Events Within 7 Days After Vaccination: Cohort 1
Percentage of participantsCohort 1: 20vPnC: >=15 to <24 Months
Fever: >=38.0 degrees C11.8 (7.7 to 17.0)
Fever: >=38.0 degrees C to 38.4 degrees C5.9 (3.1 to 10.0)
Fever: >38.4 degrees C to 38.9 degrees C2.9 (1.1 to 6.3)
Fever: >38.9 degrees C to 40.0 degrees C2.9 (1.1 to 6.3)
Fever: >40.0 degrees C0 (0.0 to 1.8)
Decreased appetite: Any25.0 (19.2 to 31.5)
Decreased appetite: Mild17.6 (12.7 to 23.6)
Decreased appetite: Moderate6.4 (3.4 to 10.7)
Decreased appetite: Severe1.0 (0.1 to 3.5)
Drowsiness/increased sleep: Any41.7 (34.8 to 48.8)
Drowsiness/increased sleep: Mild31.4 (25.1 to 38.2)
Drowsiness/increased sleep: Moderate9.3 (5.7 to 14.2)
Drowsiness/increased sleep: Severe1.0 (0.1 to 3.5)
Irritability: Any61.8 (54.7 to 68.5)
Irritability: Mild22.5 (17.0 to 28.9)
Irritability: Moderate37.3 (30.6 to 44.3)
Irritability: Severe2.0 (0.5 to 4.9)
PrimaryPercentage of Participants Reporting Prompted Systemic Events Within 7 Days After Vaccination: Cohorts 2, 3 and 4

Systemic events for Cohort 2-4 included fever, fatigue, headache, muscle pain and joint pain, recorded by parents/legal guardians of participant's using an e-diary. Fever was defined as temperature \>=38.0 degrees C and categorized as \>=38.0 to 38.4 degrees C, \>38.4 to 38.9 degrees C, \>38.9 to 40.0 degrees C and \>40.0 degrees C. Fatigue, headache, muscle pain and joint pain were graded as mild (no interference with activity), moderate (some interference with activity) and severe (prevents daily routine activity). 95% CI was based on Clopper and Pearson method.

Time frame:
Within 7 days after vaccination on Day 1
Reported as:
Number · Percentage of participants
Percentage of Participants Reporting Prompted Systemic Events Within 7 Days After Vaccination: Cohorts 2, 3 and 4
Percentage of participantsCohort 2: 20vPnC: >=2 to <5 YearsCohort 3: 20vPnC: >=5 to <10 YearsCohort 4: 20vPnC: >=10 to <18 Years
Fever: >=38.0 degrees C3.3 (1.3 to 6.6)0.5 (0.0 to 2.8)0 (0.0 to 1.8)
Fever: >=38.0 degrees C to 38.4 degrees C1.4 (0.3 to 4.0)0.5 (0.0 to 2.8)0 (0.0 to 1.8)
Fever: >38.4 degrees C to 38.9 degrees C1.4 (0.3 to 4.0)0 (0.0 to 1.8)0 (0.0 to 1.8)
Fever: >38.9 degrees C to 40.0 degrees C0.5 (0.0 to 2.6)0 (0.0 to 1.8)0 (0.0 to 1.8)
Fever: >40.0 degrees C0 (0.0 to 1.7)0 (0.0 to 1.8)0 (0.0 to 1.8)
Fatigue: Any37.2 (30.7 to 44.0)28.1 (22.0 to 34.9)27.8 (21.8 to 34.5)
Fatigue: Mild21.9 (16.5 to 28.0)19.1 (13.9 to 25.3)15.6 (10.9 to 21.3)
Fatigue: Moderate14.4 (10.0 to 19.8)8.5 (5.1 to 13.3)12.2 (8.0 to 17.5)
Fatigue: Severe0.9 (0.1 to 3.3)0.5 (0.0 to 2.8)0 (0.0 to 1.8)
Headache: Any5.6 (2.9 to 9.5)18.6 (13.4 to 24.7)29.3 (23.1 to 36.0)
Headache: Mild3.3 (1.3 to 6.6)14.6 (10.0 to 20.3)20.0 (14.8 to 26.1)
Headache: Moderate1.9 (0.5 to 4.7)3.0 (1.1 to 6.4)7.8 (4.5 to 12.4)
Headache: Severe0.5 (0.0 to 2.6)1.0 (0.1 to 3.6)1.5 (0.3 to 4.2)
Muscle pain: Any26.5 (20.7 to 32.9)39.2 (32.4 to 46.3)48.3 (41.3 to 55.4)
Muscle pain: Mild17.7 (12.8 to 23.4)26.6 (20.6 to 33.3)34.6 (28.1 to 41.6)
Muscle pain: Moderate8.4 (5.0 to 12.9)11.1 (7.1 to 16.3)13.2 (8.9 to 18.6)
Muscle pain: Severe0.5 (0.0 to 2.6)1.5 (0.3 to 4.3)0.5 (0.0 to 2.7)
Joint pain: Any3.7 (1.6 to 7.2)6.5 (3.5 to 10.9)8.3 (4.9 to 12.9)
Joint pain: Mild2.3 (0.8 to 5.3)3.0 (1.1 to 6.4)3.4 (1.4 to 6.9)
Joint pain: Moderate1.4 (0.3 to 4.0)3.0 (1.1 to 6.4)4.9 (2.4 to 8.8)
Joint pain: Severe0 (0.0 to 1.7)0.5 (0.0 to 2.8)0 (0.0 to 1.8)
PrimaryPercentage of Participants Reporting Adverse Events (AEs) up to 1 Month After Vaccination

An AE was any untoward medical occurrence in a participant, temporally associated with the use of study treatment, whether or not considered related to the study treatment. 95% CI was based on the Clopper and Pearson method. Only AEs collected by non-systematic assessment (i.e. excluding local reactions and systemic events) were reported in this outcome measure.

Time frame:
From vaccination (on Day 1) up to 1 month after vaccination
Reported as:
Number · Percentage of participants
Percentage of Participants Reporting Adverse Events (AEs) up to 1 Month After Vaccination
Percentage of participantsCohort 1: 20vPnC: >=15 to <24 MonthsCohort 2: 20vPnC: >=2 to <5 YearsCohort 3: 20vPnC: >=5 to <10 YearsCohort 4: 20vPnC: >=10 to <18 Years
Percentage of Participants Reporting Adverse Events (AEs) up to 1 Month After Vaccination23.9 ± 18.37.9 ± 4.76.5 ± 3.54.4 ± 2.0
PrimaryPercentage of Participants Reporting Serious Adverse Events (SAEs) up to 6 Months After Vaccination

An SAE was any untoward medical occurrence that occurred, at any dose: resulted in death; required inpatient hospitalization or prolongation of existing hospitalization; was life-threatening; resulted in persistent or significant disability/ incapacity; was a congenital anomaly/birth defect and other important medical events. 95% CI was based on the Clopper and Pearson method.

Time frame:
From vaccination (on Day 1) up to 6 months after vaccination
Reported as:
Number · Percentage of participants
Percentage of Participants Reporting Serious Adverse Events (SAEs) up to 6 Months After Vaccination
Percentage of participantsCohort 1: 20vPnC: >=15 to <24 MonthsCohort 2: 20vPnC: >=2 to <5 YearsCohort 3: 20vPnC: >=5 to <10 YearsCohort 4: 20vPnC: >=10 to <18 Years
Percentage of Participants Reporting Serious Adverse Events (SAEs) up to 6 Months After Vaccination1.0 (0.1 to 3.4)0 (0.0 to 1.7)0 (0.0 to 1.8)1.5 (0.3 to 4.2)
PrimaryPercentage of Participants Reporting Newly Diagnosed Chronic Medical Conditions (NDCMCs) up to 6 Months After Vaccination

An NDCMC was defined as a disease or medical condition, not previously identified, that was expected to be persistent or was otherwise long-lasting in its effects. 95% CI was based on the Clopper and Pearson method.

Time frame:
From vaccination (on Day 1) up to 6 months after vaccination
Reported as:
Number · Percentage of participants
Percentage of Participants Reporting Newly Diagnosed Chronic Medical Conditions (NDCMCs) up to 6 Months After Vaccination
Percentage of participantsCohort 1: 20vPnC: >=15 to <24 MonthsCohort 2: 20vPnC: >=2 to <5 YearsCohort 3: 20vPnC: >=5 to <10 YearsCohort 4: 20vPnC: >=10 to <18 Years
Percentage of Participants Reporting Newly Diagnosed Chronic Medical Conditions (NDCMCs) up to 6 Months After Vaccination3.3 (1.4 to 6.8)0.5 (0.0 to 2.6)0.5 (0.0 to 2.7)1.0 (0.1 to 3.5)
PrimaryGeometric Mean Fold Rises (GMFRs) of Pneumococcal Serotype-Specific Immunoglobulin G (IgG) Concentrations for the 7 Additional Serotypes From Before to 1 Month After 20vPnC Vaccination: Cohort 1 and 2

Pneumococcal serotype-specific IgG concentrations were measured from serum samples for the 7 additional 20vPnC serotypes: 8, 10A, 11A, 12F, 15B, 22F and 33F. GMFR = geometric mean of fold rise from before vaccination on Day 1 to 1 month after vaccination with 20vPnC. GMFRs and corresponding 2-sided 95% CIs were calculated by exponentiating the mean logarithm of fold rises and the corresponding 2-sided 95% CIs (based on Student's t distribution). Superiority of IgG concentration 1 month after 20vPnC to before vaccination for each serotype was demonstrated if the 95% lower CI of GMFR was \>1.

Time frame:
Before vaccination on Day 1 to 1 month after vaccination
Reported as:
Geometric mean · Fold rise
Geometric Mean Fold Rises (GMFRs) of Pneumococcal Serotype-Specific Immunoglobulin G (IgG) Concentrations for the 7 Additional Serotypes From Before to 1 Month After 20vPnC Vaccination: Cohort 1 and 2
Fold riseCohort 1: 20vPnC: >=15 to <24 MonthsCohort 2: 20vPnC: >=2 to <5 Years
Serotype 8113.4 (93.2 to 137.9)107.0 (86.1 to 133.0)
Serotype 10A83.2 (69.1 to 100.2)106.7 (86.2 to 132.0)
Serotype 11A62.7 (49.9 to 78.8)43.6 (33.2 to 57.1)
Serotype 12F27.9 (22.9 to 34.1)36.6 (30.1 to 44.7)
Serotype 15B52.1 (43.2 to 62.8)73.3 (58.7 to 91.5)
Serotype 22F1847.7 (1481.3 to 2304.5)796.2 (577.1 to 1098.4)
Serotype 33F113.5 (92.5 to 139.2)78.3 (61.6 to 99.5)
PrimaryGMFRs of Pneumococcal Serotype-Specific Opsonophagocytic Activity (OPA) Titers for the 7 Additional Serotypes From Before to 1 Month After 20vPnC Vaccination: Cohort 3 and 4

Pneumococcal serotype-specific OPA titers were measured from serum samples for 7 the additional 20vPnC serotypes: 8, 10A, 11A, 12F, 15B, 22F and 33F. GMFR = geometric mean of fold rise from before vaccination on Day 1 to 1 month after vaccination with 20vPnC. GMFRs and the corresponding 2-sided 95% CIs were calculated by exponentiating the mean logarithm of fold rises and the corresponding 2-sided 95% CIs (based on the Student's t distribution). Superiority of OPA titers 1 month after 20vPnC to before vaccination for each serotype was demonstrated if the 95% lower CI of the GMFR was \>1.

Time frame:
Before vaccination on Day 1 to 1 month after vaccination
Reported as:
Geometric mean · Fold rise
GMFRs of Pneumococcal Serotype-Specific Opsonophagocytic Activity (OPA) Titers for the 7 Additional Serotypes From Before to 1 Month After 20vPnC Vaccination: Cohort 3 and 4
Fold riseCohort 3: 20vPnC: >=5 to <10 YearsCohort 4: 20vPnC: >=10 to <18 Years
Serotype 8106.5 (79.9 to 142.0)86.3 (64.2 to 115.9)
Serotype 10A30.6 (20.1 to 46.6)33.5 (22.3 to 50.1)
Serotype 11A11.6 (7.6 to 17.7)14.9 (10.2 to 21.8)
Serotype 12F463.6 (332.3 to 646.7)454.1 (333.3 to 618.7)
Serotype 15B380.8 (228.3 to 635.2)499.0 (338.7 to 735.3)
Serotype 22F128.5 (76.7 to 215.3)111.2 (67.1 to 184.3)
Serotype 33F14.2 (10.9 to 18.4)11.5 (8.9 to 14.9)
SecondaryPercentage of Participants With Predefined Levels of Pneumococcal Serotype-Specific IgG Concentrations for the 7 Additional Serotypes at 1 Month After Vaccination in Cohort 1 Only

Pneumococcal serotype-specific IgG concentrations were measured from serum samples for the 7 additional 20vPnC serotypes: 8, 10A, 11A, 12F, 15B, 22F and 33F. Percentage of participants with predefined level (\>=0.35 micrograms per milliliter) of IgG concentration for the 7 additional 20vPnC serotypes was presented. 2-sided 95% CI was based on Clopper and Pearson method.

Time frame:
At 1 Month after vaccination on Day 1
Reported as:
Number · Percentage of participants
Percentage of Participants With Predefined Levels of Pneumococcal Serotype-Specific IgG Concentrations for the 7 Additional Serotypes at 1 Month After Vaccination in Cohort 1 Only
Percentage of participantsCohort 1: 20vPnC: >=15 to <24 Months
Serotype 8100.0 ± 98.1
Serotype 10A83.2 ± 77.1
Serotype 11A93.2 ± 88.6
Serotype 12F40.0 ± 33.0
Serotype 15B83.7 ± 77.6
Serotype 22F98.9 ± 96.2
Serotype 33F92.6 ± 87.9
SecondaryPercentage of Participants With >=4-fold Rise in Pneumococcal Serotype-Specific OPA Titers for the 7 Additional Serotypes From Before to 1 Month After Vaccination: Cohorts 2, 3, and 4 Only

Pneumococcal serotype-specific OPA titers were measured from serum samples for 7 additional 20vPnC serotypes: 8, 10A, 11A, 12F, 15B, 22F and 33F. Percentage of participants with \>=4-fold rise in serotype-specific OPA titers from before vaccination to 1 month after vaccination with 20vPnC and the associated 2-sided 95% CI based on the Clopper and Pearson method was presented. OPA titers were measured in a randomized subset of samples in Cohort 2 for this outcome measure.

Time frame:
Before vaccination on Day 1 to 1 month after vaccination
Reported as:
Number · Percentage of participants
Percentage of Participants With >=4-fold Rise in Pneumococcal Serotype-Specific OPA Titers for the 7 Additional Serotypes From Before to 1 Month After Vaccination: Cohorts 2, 3, and 4 Only
Percentage of participantsCohort 2: 20vPnC: >=2 to <5 YearsCohort 3: 20vPnC: >=5 to <10 YearsCohort 4: 20vPnC: >=10 to <18 Years
Serotype 893.2 (84.9 to 97.8)92.2 (86.7 to 95.9)89.1 (83.5 to 93.3)
Serotype 10A84.9 (74.6 to 92.2)80.6 (72.9 to 86.9)81.7 (74.3 to 87.7)
Serotype 11A86.5 (74.2 to 94.4)66.2 (57.6 to 74.1)62.6 (54.5 to 70.2)
Serotype: 12F94.6 (86.7 to 98.5)96.8 (92.6 to 98.9)94.5 (89.8 to 97.5)
Serotype: 15B88.2 (78.7 to 94.4)89.4 (83.2 to 94.0)93.9 (89.1 to 97.0)
Serotype: 22F86.8 (76.4 to 93.8)87.6 (80.9 to 92.6)81.0 (74.2 to 86.6)
Serotype: 33F71.2 (59.4 to 81.2)79.9 (72.4 to 86.1)75.3 (67.8 to 81.8)
SecondaryGeometric Mean Concentrations (GMCs) of Pneumococcal Serotype-Specific IgG for the 20vPnC Serotypes Before and 1 Month After Vaccination

Pneumococcal serotype-specific IgG concentrations were measured for serum samples for 13vPnC serotypes: 1, 3, 4, 5, 6A, 6B, 7F, 9V, 14, 18C, 19A, 19F, and 23F; and 7 additional 20vPnC serotypes: 8, 10A, 11A, 12F, 15B, 22F and 33F. GMCs the corresponding 2-sided 95% CIs were calculated by exponentiating the mean logarithm of the concentrations and the corresponding 2-sided 95% CIs (based on the Student's t distribution).

Time frame:
Before vaccination and 1 month after vaccination
Reported as:
Geometric mean · Micrograms per milliliter
Geometric Mean Concentrations (GMCs) of Pneumococcal Serotype-Specific IgG for the 20vPnC Serotypes Before and 1 Month After Vaccination
Micrograms per milliliterCohort 1: 20vPnC: >=15 to <24 MonthsCohort 2: 20vPnC: >=2 to <5 YearsCohort 3: 20vPnC: >=5 to <10 YearsCohort 4: 20vPnC: >=10 to <18 Years
Before Vaccination, Serotype 10.43 (0.37 to 0.49)0.20 (0.17 to 0.24)0.12 (0.10 to 0.14)0.09 (0.08 to 0.11)
1 Month after Vaccination, Serotype 11.46 (1.28 to 1.67)4.21 (3.62 to 4.90)5.86 (5.15 to 6.67)4.04 (3.32 to 4.93)
Before Vaccination, Serotype 30.14 (0.12 to 0.16)0.08 (0.06 to 0.10)0.22 (0.17 to 0.30)0.15 (0.11 to 0.20)
1 Month after Vaccination, Serotype 30.54 (0.47 to 0.61)1.21 (1.04 to 1.42)1.32 (1.16 to 1.50)0.62 (0.52 to 0.76)
Before Vaccination, Serotype 40.61 (0.52 to 0.72)0.30 (0.25 to 0.37)0.13 (0.11 to 0.16)0.12 (0.10 to 0.15)
1 Month after Vaccination, Serotype 42.59 (2.27 to 2.96)8.37 (7.28 to 9.62)9.76 (8.54 to 11.15)6.37 (5.39 to 7.53)
Before Vaccination, Serotype 50.43 (0.36 to 0.50)0.18 (0.15 to 0.22)0.07 (0.06 to 0.08)0.04 (0.03 to 0.06)
1 Month after Vaccination, Serotype 51.53 (1.32 to 1.77)5.09 (4.32 to 5.99)7.50 (6.52 to 8.63)2.58 (1.88 to 3.53)
Before Vaccination, Serotype 6A1.61 (1.38 to 1.88)0.71 (0.58 to 0.88)0.50 (0.39 to 0.65)0.28 (0.22 to 0.37)
1 Month after Vaccination, Serotype 6A7.59 (6.67 to 8.63)31.99 (27.85 to 36.75)46.28 (39.90 to 53.67)20.03 (15.39 to 26.07)
Before Vaccination, Serotype 6B0.85 (0.71 to 1.02)0.52 (0.42 to 0.63)0.26 (0.20 to 0.32)0.40 (0.31 to 0.51)
1 Month after Vaccination, Serotype 6B4.27 (3.69 to 4.94)17.78 (15.43 to 20.48)32.45 (27.90 to 37.74)38.82 (31.49 to 47.86)
Before Vaccination, Serotype 7F1.17 (1.03 to 1.33)0.51 (0.44 to 0.60)0.18 (0.16 to 0.21)0.11 (0.08 to 0.14)
1 Month after Vaccination, Serotype 7F3.53 (3.16 to 3.94)6.42 (5.69 to 7.24)7.92 (7.03 to 8.93)3.19 (2.65 to 3.85)
Before Vaccination, Serotype 9V0.71 (0.61 to 0.83)0.35 (0.28 to 0.42)0.14 (0.11 to 0.17)0.14 (0.11 to 0.18)
1 Month after Vaccination, Serotype 9V2.70 (2.35 to 3.09)7.94 (6.83 to 9.24)10.86 (9.41 to 12.54)7.67 (6.52 to 9.02)
Before Vaccination, Serotype 141.53 (1.31 to 1.79)0.66 (0.53 to 0.81)0.42 (0.33 to 0.53)0.29 (0.23 to 0.37)
1 Month after Vaccination, Serotype 144.42 (3.82 to 5.12)14.60 (12.44 to 17.13)28.54 (24.77 to 32.89)28.17 (23.90 to 33.21)
Before Vaccination, Serotype 18C0.65 (0.55 to 0.76)0.26 (0.21 to 0.32)0.12 (0.09 to 0.14)0.13 (0.11 to 0.17)
1 Month after Vaccination, Serotype 18C2.69 (2.32 to 3.12)7.07 (6.01 to 8.32)10.83 (9.53 to 12.30)8.61 (7.34 to 10.10)
Before Vaccination, Serotype 19A0.47 (0.38 to 0.58)0.52 (0.40 to 0.68)0.78 (0.58 to 1.04)0.55 (0.43 to 0.70)
1 Month after Vaccination, Serotype 19A3.29 (2.89 to 3.76)12.48 (10.76 to 14.48)13.65 (11.96 to 15.59)8.89 (7.29 to 10.84)
Before Vaccination, Serotype 19F0.80 (0.67 to 0.94)0.56 (0.44 to 0.71)0.96 (0.70 to 1.32)0.82 (0.63 to 1.06)
1 Month after Vaccination, Serotype 19F4.16 (3.61 to 4.79)12.50 (10.48 to 14.91)14.62 (12.32 to 17.36)6.55 (5.60 to 7.66)
Before Vaccination, Serotype 23F0.96 (0.79 to 1.18)0.90 (0.71 to 1.15)0.82 (0.64 to 1.06)0.61 (0.48 to 0.78)
1 Month after Vaccination, Serotype 23F5.35 (4.55 to 6.30)16.18 (13.75 to 19.04)22.69 (19.40 to 26.53)19.16 (16.31 to 22.51)
Before Vaccination, Serotype 80.04 (0.03 to 0.05)0.05 (0.04 to 0.06)0.08 (0.07 to 0.10)0.16 (0.12 to 0.20)
1 Month after Vaccination, Serotype 84.66 (4.17 to 5.22)5.08 (4.45 to 5.80)4.65 (4.05 to 5.34)4.26 (3.67 to 4.94)
Before Vaccination, Serotype 10A0.01 (0.01 to 0.02)0.03 (0.02 to 0.03)0.07 (0.06 to 0.09)0.15 (0.12 to 0.19)
1 Month after Vaccination, Serotype 10A1.23 (1.02 to 1.48)2.76 (2.28 to 3.34)3.98 (3.25 to 4.88)5.35 (4.20 to 6.81)
Before Vaccination, Serotype 11A0.03 (0.02 to 0.03)0.06 (0.04 to 0.08)0.12 (0.09 to 0.16)0.30 (0.23 to 0.38)
1 Month after Vaccination, Serotype 11A1.61 (1.40 to 1.86)2.64 (2.25 to 3.09)2.80 (2.35 to 3.33)3.13 (2.60 to 3.77)
Before Vaccination, Serotype 12F0.01 (0.01 to 0.01)0.01 (0.01 to 0.01)0.01 (0.01 to 0.01)0.01 (0.01 to 0.01)
1 Month after Vaccination, Serotype 12F0.22 (0.18 to 0.27)0.38 (0.31 to 0.46)0.36 (0.29 to 0.44)0.28 (0.22 to 0.34)
Before Vaccination, Serotype 15B0.02 (0.02 to 0.03)0.05 (0.04 to 0.07)0.20 (0.15 to 0.27)0.35 (0.27 to 0.45)
1 Month after Vaccination, Serotype 15B1.17 (0.97 to 1.40)3.96 (3.12 to 5.03)10.74 (8.49 to 13.60)18.79 (15.16 to 23.28)
Before Vaccination, Serotype 22F0.01 (0.00 to 0.01)0.02 (0.01 to 0.02)0.08 (0.06 to 0.11)0.14 (0.11 to 0.19)
1 Month after Vaccination, Serotype 22F9.57 (8.12 to 11.29)12.46 (10.82 to 14.35)15.68 (13.45 to 18.29)12.36 (10.38 to 14.72)
Before Vaccination, Serotype 33F0.02 (0.01 to 0.02)0.04 (0.03 to 0.05)0.10 (0.08 to 0.12)0.18 (0.14 to 0.22)
1 Month after Vaccination, Serotype 33F1.91 (1.60 to 2.27)3.16 (2.63 to 3.79)3.87 (3.24 to 4.61)3.93 (3.25 to 4.75)
SecondaryGMFRs of Pneumococcal Serotype-Specific IgG Concentrations for the 13vPnC Serotypes From Before to 1 Month After Vaccination: Cohort 1 and 2

Pneumococcal serotype-specific IgG concentrations were measured from serum samples for 13vPnC serotypes: 1, 3, 4, 5, 6A, 6B, 7F, 9V, 14, 18C, 19A, 19F and 23F. GMFR = geometric mean of fold rise from before vaccination on Day 1 to 1 month after vaccination with 20vPnC. GMFRs and the corresponding 2-sided 95% CIs were calculated by exponentiating the mean logarithm of the fold rises and the corresponding 2-sided 95% CIs (based on the Student's t distribution).

Time frame:
Before vaccination on Day 1 to 1 month after vaccination
Reported as:
Geometric mean · Fold rise
GMFRs of Pneumococcal Serotype-Specific IgG Concentrations for the 13vPnC Serotypes From Before to 1 Month After Vaccination: Cohort 1 and 2
Fold riseCohort 1: 20vPnC: >=15 to <24 MonthsCohort 2: 20vPnC: >=2 to <5 Years
Serotype 13.4 (3.0 to 3.9)20.6 (17.2 to 24.7)
Serotype 33.9 (3.4 to 4.5)14.9 (12.4 to 17.9)
Serotype 44.3 (3.7 to 5.0)27.6 (22.7 to 33.5)
Serotype 53.6 (3.1 to 4.2)28.2 (23.0 to 34.6)
Serotype 6A4.8 (4.1 to 5.6)44.9 (35.8 to 56.3)
Serotype 6B5.0 (4.3 to 5.9)34.5 (28.3 to 42.0)
Serotype 7F3.0 (2.7 to 3.4)12.5 (10.5 to 14.9)
Serotype 9V3.8 (3.3 to 4.4)23.0 (19.0 to 27.8)
Serotype 142.9 (2.5 to 3.3)22.2 (18.0 to 27.4)
Serotype 18C4.2 (3.6 to 4.9)27.2 (22.5 to 32.9)
Serotype 19A6.9 (5.7 to 8.4)24.1 (19.0 to 30.6)
Serotype 19F5.2 (4.4 to 6.3)22.3 (17.2 to 28.8)
Serotype 23F5.6 (4.8 to 6.6)17.9 (14.6 to 21.9)
SecondaryGMFRs of Pneumococcal Serotype-Specific IgG Concentrations for the 20vPnC Serotypes From Before to 1 Month After Vaccination: Cohort 3 and 4

Pneumococcal serotype-specific IgG concentrations were measured from serum samples for 13vPnC serotypes: 1, 3, 4, 5, 6A, 6B, 7F, 9V, 14, 18C, 19A, 19F and 23F; and 7 additional 20vPnC serotypes: 8, 10A, 11A, 12F, 15B, 22F and 33F. GMFR = geometric mean of fold rise from before vaccination on Day 1 to 1 month after vaccination with 20vPnC. GMFRs and the corresponding 2-sided 95% CIs were calculated by exponentiating the mean logarithm of the fold rises and the corresponding 2-sided 95% CIs (based on the Student's t distribution).

Time frame:
Before vaccination on Day 1 to 1 month after vaccination
Reported as:
Geometric mean · Fold rise
GMFRs of Pneumococcal Serotype-Specific IgG Concentrations for the 20vPnC Serotypes From Before to 1 Month After Vaccination: Cohort 3 and 4
Fold riseCohort 3: 20vPnC: >=5 to <10 YearsCohort 4: 20vPnC: >=10 to <18 Years
Serotype 149.4 (41.6 to 58.6)44.2 (37.0 to 52.9)
Serotype 35.9 (4.6 to 7.5)4.3 (3.5 to 5.2)
Serotype 474.1 (61.4 to 89.4)52.0 (42.3 to 64.0)
Serotype 5107.0 (89.4 to 128.2)59.3 (47.6 to 73.9)
Serotype 6A91.9 (67.7 to 124.9)72.5 (54.9 to 95.7)
Serotype 6B127.9 (101.0 to 162.0)99.5 (77.1 to 128.3)
Serotype 7F42.9 (36.1 to 51.1)30.0 (24.0 to 37.6)
Serotype 9V80.3 (64.3 to 100.3)54.2 (42.7 to 68.9)
Serotype 1468.4 (53.4 to 87.7)96.7 (76.6 to 122.1)
Serotype 18C93.7 (76.9 to 114.1)64.5 (52.3 to 79.4)
Serotype 19A17.6 (13.2 to 23.4)16.2 (13.1 to 20.0)
Serotype 19F15.2 (10.5 to 22.0)8.0 (6.0 to 10.7)
Serotype 23F27.6 (21.0 to 36.3)31.4 (23.8 to 41.5)
Serotype 855.2 (44.8 to 67.9)27.3 (21.9 to 33.9)
Serotype 10A54.8 (44.4 to 67.7)35.9 (29.3 to 43.9)
Serotype 11A23.6 (18.6 to 29.9)10.5 (8.5 to 12.9)
Serotype 12F31.9 (26.7 to 38.3)21.4 (17.6 to 26.0)
Serotype 15B52.6 (41.3 to 66.9)53.8 (43.1 to 67.1)
Serotype 22F187.7 (134.6 to 261.7)86.2 (64.9 to 114.4)
Serotype 33F39.3 (31.6 to 49.0)22.4 (18.2 to 27.6)
SecondaryGeometric Mean Titers (GMTs) of Pneumococcal Serotype-Specific OPA Titers for the 20vPnC Serotypes Before and 1 Month After Vaccination

Pneumococcal serotype-specific OPA titers were measured from serum samples for 13vPnC serotypes: 1, 3, 4, 5, 6A, 6B, 7F, 9V, 14, 18C, 19A, 19F, and 23F; and 7 additional 20vPnC serotypes: 8, 10A, 11A, 12F, 15B, 22F and 33F. GMTs and 2-sided 95% CIs were calculated by exponentiating the mean logarithm of the titers and the corresponding 2-sided 95% CIs (based on the Student's t distribution). OPA titers were measured in a randomized subset of serum samples in Cohorts 1 and 2. OPA titers for the 13vPnC serotypes were measured in a randomized subset of serum samples in Cohorts 3 and 4.

Time frame:
Before vaccination on Day 1 and 1 month after vaccination
Reported as:
Geometric mean · Titer
Geometric Mean Titers (GMTs) of Pneumococcal Serotype-Specific OPA Titers for the 20vPnC Serotypes Before and 1 Month After Vaccination
TiterCohort 1: 20vPnC: >=15 to <24 MonthsCohort 2: 20vPnC: >=2 to <5 YearsCohort 3: 20vPnC: >=5 to <10 YearsCohort 4: 20vPnC: >=10 to <18 Years
Before Vaccination, Serotype 114 (11 to 18)12 (10 to 14)10 (9 to 11)11 (9 to 12)
1 Month after Vaccination, Serotype 157 (39 to 84)360 (272 to 476)548 (455 to 660)396 (302 to 519)
Before Vaccination, Serotype 321 (15 to 29)15 (11 to 22)29 (22 to 40)19 (14 to 24)
1 Month after Vaccination, Serotype 380 (62 to 103)150 (116 to 195)155 (135 to 178)105 (88 to 124)
Before Vaccination, Serotype 442 (24 to 75)34 (19 to 62)43 (27 to 67)34 (22 to 51)
1 Month after Vaccination, Serotype 4563 (342 to 927)1729 (1188 to 2516)2328 (1942 to 2789)2290 (1822 to 2878)
Before Vaccination, Serotype 518 (16 to 21)17 (15 to 20)15 (15 to 15)15 (15 to 16)
1 Month after Vaccination, Serotype 551 (38 to 68)198 (143 to 276)385 (324 to 458)216 (159 to 294)
Before Vaccination, Serotype 6A137 (77 to 243)96 (55 to 168)74 (51 to 106)64 (44 to 91)
1 Month after Vaccination, Serotype 6A1707 (1144 to 2547)5283 (3954 to 7060)8268 (6617 to 10331)9434 (7616 to 11686)
Before Vaccination, Serotype 6B110 (67 to 182)126 (72 to 219)156 (99 to 244)237 (155 to 363)
1 Month after Vaccination, Serotype 6B943 (611 to 1455)3273 (2390 to 4482)6569 (5367 to 8040)10085 (8263 to 12309)
Before Vaccination, Serotype 7F705 (492 to 1010)996 (748 to 1327)541 (410 to 713)516 (381 to 698)
1 Month after Vaccination, Serotype 7F2635 (2105 to 3297)3409 (2552 to 4556)3981 (3446 to 4598)3326 (2878 to 3843)
Before Vaccination, Serotype 9V649 (350 to 1204)323 (202 to 515)410 (289 to 580)469 (330 to 667)
1 Month after Vaccination, Serotype 9V7686 (5718 to 10332)7210 (4781 to 10876)11717 (9262 to 14823)9627 (7492 to 12369)
Before Vaccination, Serotype 14242 (151 to 387)300 (186 to 484)246 (172 to 353)97 (65 to 145)
1 Month after Vaccination, Serotype 141018 (748 to 1385)2506 (1932 to 3249)4610 (3688 to 5762)3925 (3153 to 4885)
Before Vaccination, Serotype 18C300 (147 to 613)139 (69 to 277)152 (89 to 261)73 (45 to 119)
1 Month after Vaccination, Serotype 18C3749 (2740 to 5131)5344 (3809 to 7498)6766 (5585 to 8197)3617 (2816 to 4645)
Before Vaccination, Serotype 19A138 (71 to 271)84 (45 to 156)117 (76 to 181)66 (44 to 100)
1 Month after Vaccination, Serotype 19A1708 (1192 to 2448)2640 (1943 to 3587)2162 (1786 to 2618)2212 (1801 to 2717)
Before Vaccination, Serotype 19F44 (31 to 61)44 (31 to 61)91 (66 to 125)57 (44 to 73)
1 Month after Vaccination, Serotype 19F267 (169 to 421)928 (618 to 1394)1095 (810 to 1479)551 (401 to 757)
Before Vaccination, Serotype 23F139 (67 to 288)206 (108 to 394)87 (53 to 145)46 (29 to 73)
1 Month after Vaccination, Serotype 23F1936 (1385 to 2707)2493 (1757 to 3539)2213 (1751 to 2797)1842 (1391 to 2439)
Before Vaccination, Serotype 830 (24 to 39)39 (29 to 54)34 (28 to 42)35 (28 to 43)
1 Month after Vaccination, Serotype 84758 (3763 to 6016)4428 (3467 to 5654)3870 (3302 to 4535)3125 (2680 to 3642)
Before Vaccination, Serotype 10A92 (60 to 141)275 (160 to 472)745 (519 to 1071)554 (395 to 777)
1 Month after Vaccination, Serotype 10A10626 (7825 to 14429)14345 (10473 to 19649)21102 (17238 to 25833)17417 (14301 to 21214)
Before Vaccination, Serotype 11A88 (60 to 127)436 (237 to 800)1347 (962 to 1887)765 (543 to 1076)
1 Month after Vaccination, Serotype 11A13350 (10540 to 16910)14093 (9904 to 20054)16882 (13650 to 20880)11677 (9751 to 13982)
Before Vaccination, Serotype 12F38 (29 to 50)37 (27 to 50)48 (38 to 60)46 (36 to 59)
1 Month after Vaccination, Serotype 12F16924 (13400 to 21376)13257 (9463 to 18572)23860 (19002 to 29959)20250 (16861 to 24320)
Before Vaccination, Serotype 15B30 (21 to 45)111 (63 to 197)79 (54 to 115)45 (33 to 61)
1 Month after Vaccination, Serotype 15B22951 (17380 to 30307)27095 (19557 to 37538)25729 (19647 to 33695)21496 (16697 to 27672)
Before Vaccination, Serotype: 22F21 (13 to 33)104 (55 to 194)259 (170 to 394)243 (161 to 366)
1 Month after Vaccination, Serotype 22F22464 (16840 to 29967)25573 (18096 to 36141)33615 (26198 to 43130)27922 (22622 to 34463)
Before Vaccination, Serotype: 33F1154 (861 to 1548)2179 (1694 to 2804)3334 (2847 to 3905)2895 (2448 to 3424)
1 Month after Vaccination, Serotype 33F23431 (17375 to 31598)28076 (19255 to 40938)45921 (36768 to 57353)32363 (26219 to 39946)
SecondaryGMFRs of Pneumococcal Serotype-Specific OPA Titers for the 20vPnC Serotypes From Before to 1 Month After Vaccination: Cohorts 1 and 2

Pneumococcal serotype-specific OPA titers were measured from serum samples for 13vPnC serotypes: 1, 3, 4, 5, 6A, 6B, 7F, 9V, 14, 18C, 19A, 19F, and 23F; and 7 additional 20vPnC serotypes: 8, 10A, 11A, 12F, 15B, 22F and 33F. GMFR = geometric mean of fold rise from before vaccination on Day 1 to 1 month after vaccination with 20vPnC. GMFRs and the corresponding 2-sided 95% CIs were calculated by exponentiating the mean logarithm of the fold rises and the corresponding 2-sided 95% CIs (based on the Student's t distribution). OPA titers measured in a randomized subset of serum samples in Cohorts 1 and 2 for this outcome measure.

Time frame:
Before vaccination on Day 1 to 1 month after vaccination
Reported as:
Geometric mean · Fold rise
GMFRs of Pneumococcal Serotype-Specific OPA Titers for the 20vPnC Serotypes From Before to 1 Month After Vaccination: Cohorts 1 and 2
Fold riseCohort 1: 20vPnC: >=15 to <24 MonthsCohort 2: 20vPnC: >=2 to <5 Years
Serotype 14.1 (2.9 to 6.0)29.8 (21.2 to 41.9)
Serotype 33.7 (2.6 to 5.3)9.6 (7.1 to 13.1)
Serotype 413.2 (7.0 to 25.0)50.0 (26.7 to 93.6)
Serotype 52.8 (2.0 to 3.8)11.4 (8.2 to 16.0)
Serotype 6A12.7 (8.1 to 20.0)52.9 (30.8 to 90.9)
Serotype 6B7.8 (4.6 to 13.2)24.4 (14.4 to 41.2)
Serotype 7F3.6 (2.5 to 5.2)3.6 (2.7 to 4.8)
Serotype 9V11.5 (6.2 to 21.3)23.1 (14.7 to 36.5)
Serotype 143.9 (2.5 to 6.1)8.3 (5.1 to 13.4)
Serotype 18C12.7 (6.6 to 24.5)40.6 (20.7 to 79.6)
Serotype 19A11.1 (6.2 to 19.8)33.5 (17.3 to 65.0)
Serotype 19F5.7 (3.3 to 9.7)21.0 (13.0 to 33.9)
Serotype 23F12.5 (6.7 to 23.6)10.7 (6.2 to 18.5)
Serotype 8155.9 (110.4 to 220.2)105.4 (67.6 to 164.3)
Serotype 10A121.7 (74.7 to 198.4)53.3 (28.7 to 99.0)
Serotype 11A161.4 (115.7 to 225.2)34.7 (17.1 to 70.4)
Serotype 12F437.2 (307.0 to 622.7)319.9 (193.9 to 527.9)
Serotype 15B717.6 (449.8 to 1144.6)294.4 (149.1 to 581.3)
Serotype 22F983.6 (580.9 to 1665.5)224.6 (104.9 to 480.9)
Serotype 33F18.8 (13.1 to 27.2)12.4 (7.4 to 20.7)
SecondaryGMFRs of Pneumococcal Serotype-Specific OPA Titers for the 13vPnC Serotypes From Before to 1 Month After Vaccination: Cohorts 3 and 4

Pneumococcal serotype-specific OPA titers were measured for 13vPnC serotypes: 1, 3, 4, 5, 6A, 6B, 7F, 9V, 14, 18C, 19A, 19F, and 23F. GMFR = geometric mean of fold rise from before vaccination on Day 1 to 1 month after vaccination with 20vPnC. GMFRs and the corresponding 2-sided 95% CIs were calculated by exponentiating the mean logarithm of the fold rises and the corresponding 2-sided 95% CIs (based on the Student's t distribution). OPA titers for the 13vPnC serotypes were measured in a randomized subset of serum samples in Cohorts 3 and 4.

Time frame:
Before vaccination on Day 1 to 1 month after vaccination
Reported as:
Geometric mean · Fold rise
GMFRs of Pneumococcal Serotype-Specific OPA Titers for the 13vPnC Serotypes From Before to 1 Month After Vaccination: Cohorts 3 and 4
Fold riseCohort 3: 20vPnC: >=5 to <10 YearsCohort 4: 20vPnC: >=10 to <18 Years
Serotype 155.2 (45.1 to 67.4)37.3 (28.7 to 48.6)
Serotype 35.3 (3.9 to 7.2)5.8 (4.5 to 7.5)
Serotype 450.2 (31.6 to 79.5)65.6 (41.4 to 103.7)
Serotype 526.7 (22.4 to 31.8)14.4 (10.5 to 19.6)
Serotype 6A110.3 (68.7 to 177.1)147.9 (96.0 to 228.0)
Serotype 6B38.8 (22.7 to 66.3)42.0 (26.1 to 67.6)
Serotype 7F7.0 (5.3 to 9.3)6.2 (4.4 to 8.8)
Serotype 9V28.9 (19.7 to 42.5)20.4 (13.4 to 31.0)
Serotype 1418.1 (12.2 to 26.8)38.9 (25.1 to 60.3)
Serotype 18C46.2 (26.8 to 79.6)47.3 (28.7 to 78.0)
Serotype 19A17.5 (10.8 to 28.3)33.1 (20.7 to 53.1)
Serotype 19F11.7 (7.4 to 18.5)10.0 (6.7 to 15.0)
Serotype 23F26.9 (16.3 to 44.5)39.4 (23.7 to 65.7)

Adverse events

Collected over Local reactions and systemic events (systematic assessment): within 7 days after vaccination; SAEs (non-systematic assessment): from Day 1 up to 6 months after vaccination and other AEs (non-systematic assessment): from Day1 up to 1 month after vaccination. Non-serious events are listed at a 5% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
Cohort 1: 20vPnC: >=15 to <24 Months0/209 (0%)2/209 (1%)173/209 (82.8%)
Cohort 2: 20vPnC: >=2 to <5 Years0/216 (0%)0/216 (0%)163/216 (75.5%)
Cohort 3: 20vPnC: >=5 to <10 Years0/201 (0%)0/201 (0%)178/201 (88.6%)
Cohort 4: 20vPnC: >=10 to <18 Years0/205 (0%)3/205 (1.5%)186/205 (90.7%)
Most frequent serious events
Most frequent serious events
EventCohort 1: 20vPnC: >=15 to <24 MonthsCohort 2: 20vPnC: >=2 to <5 YearsCohort 3: 20vPnC: >=5 to <10 YearsCohort 4: 20vPnC: >=10 to <18 Years
AppendicitisInfections and infestations0/2090/2160/2011/205
Papillary thyroid cancerNeoplasms benign, malignant and unspecified (incl cysts and polyps)0/2090/2160/2011/205
HeadacheNervous system disorders0/2090/2160/2011/205
Near drowningInjury, poisoning and procedural complications1/2090/2160/2010/205
Febrile convulsionNervous system disorders1/2090/2160/2010/205
Most frequent other events
Showing 10 of 11
Most frequent other events
EventCohort 1: 20vPnC: >=15 to <24 MonthsCohort 2: 20vPnC: >=2 to <5 YearsCohort 3: 20vPnC: >=5 to <10 YearsCohort 4: 20vPnC: >=10 to <18 Years
Injection site pain (PAIN)General disorders107/209142/216165/201168/205
Irritability (IRRITABILITY)Psychiatric disorders126/2090/2160/2010/205
Myalgia (MUSCLE PAIN)Musculoskeletal and connective tissue disorders0/20957/21678/20199/205
Hypersomnia (INCREASED SLEEP)Nervous system disorders85/2090/2160/2010/205
Injection site erythema (REDNESS)General disorders77/20984/21674/20131/205
Fatigue (FATIGUE)General disorders0/20980/21656/20157/205
Headache (HEADACHE)Nervous system disorders0/20912/21637/20160/205
Injection site swelling (SWELLING)General disorders45/20950/21654/20132/205
Decreased appetite (DECREASED APPETITE)Metabolism and nutrition disorders51/2090/2160/2010/205
Pyrexia (FEVER)General disorders24/2097/2161/2010/205

Baseline characteristics

Enrolled population included all participants who signed informed consent form (ICF).

Age, Customized
Age, Customized(Participants)Cohort 1: 20vPnC: >=15 to <24 MonthsCohort 2: 20vPnC: >=2 to <5 YearsCohort 3: 20vPnC: >=5 to <10 YearsCohort 4: 20vPnC: >=10 to <18 YearsTotal
28 Days to 23 Months210000210
2 Years to 5 Years0219280247
6 Years to 11 Years0017551226
12 Years to 18 Years000156156
Sex: Female, Male
Sex: Female, Male(Participants)Cohort 1: 20vPnC: >=15 to <24 MonthsCohort 2: 20vPnC: >=2 to <5 YearsCohort 3: 20vPnC: >=5 to <10 YearsCohort 4: 20vPnC: >=10 to <18 YearsTotal
Female931119491389
Male117108109116450
Ethnicity (NIH/OMB)
Ethnicity (NIH/OMB)(Participants)Cohort 1: 20vPnC: >=15 to <24 MonthsCohort 2: 20vPnC: >=2 to <5 YearsCohort 3: 20vPnC: >=5 to <10 YearsCohort 4: 20vPnC: >=10 to <18 YearsTotal
Hispanic or Latino35463245158
Not Hispanic or Latino173173169161676
Unknown or Not Reported20215
Race (NIH/OMB)
Race (NIH/OMB)(Participants)Cohort 1: 20vPnC: >=15 to <24 MonthsCohort 2: 20vPnC: >=2 to <5 YearsCohort 3: 20vPnC: >=5 to <10 YearsCohort 4: 20vPnC: >=10 to <18 YearsTotal
American Indian or Alaska Native01001
Asian30003
Native Hawaiian or Other Pacific Islander00011
Black or African American2626221791
White169175176180700
More than one race10145938
Unknown or Not Reported23005
08

Study locations

43 sites
  • Northwest Arkansas Pediatrics
    Fayetteville, Arkansas 72703, United States
  • The Children's Clinic of Jonesboro, P.A.
    Jonesboro, Arkansas 72401, United States
  • The Children's Clinic
    Jonesboro, Arkansas 72401, United States
  • California Research Foundation
    San Diego, California 92123-1881, United States
  • Pharmax Research Clinic, Inc.
    Miami, Florida 33126, United States
  • Bio-Medical Research, LLC
    Miami, Florida 33184, United States
  • Children's Health Center
    Tampa, Florida 33617, United States
  • Tekton Research, Inc
    Chamblee, Georgia 30341, United States
  • Clinical Research Prime
    Idaho Falls, Idaho 83404, United States
  • Meridian Clinical Research, LLC
    Sioux City, Iowa 51106, United States
  • Alliance for Multispecialty Research, LLC
    Newton, Kansas 67114, United States
  • Kentucky Pediatric/ Adult Research
    Bardstown, Kentucky 40004, United States
  • Michael W. Simon, M.D., PSC
    Lexington, Kentucky 40517, United States
  • MedPharmics, LLC
    Gulfport, Mississippi 39503, United States
  • Velocity Clinical Research, Grand Island
    Grand Island, Nebraska 68803, United States
  • Midwest Children's Health Research Institute
    Lincoln, Nebraska 68504, United States
  • Midwest Children's Health Research Institute
    Lincoln, Nebraska 68516, United States
  • Velocity Clinical Research, Norfolk
    Norfolk, Nebraska 68701, United States
  • Meridian Clinical Research, LLC
    Omaha, Nebraska 68134, United States
  • Velocity Clinical Research, Sioux City
    Omaha, Nebraska 68134, United States
  • Wr-Crcn, Llc
    Henderson, Nevada 89014, United States
  • MedPharmic's, LLC
    Albuquerque, New Mexico 87102, United States
  • Meridian Clinical Research, LLC
    Binghamton, New York 13901, United States
  • Dayton Clinical Research
    Dayton, Ohio 45409, United States
  • Ohio Pediatric Research Association Inc.
    Dayton, Ohio 45414, United States
  • PriMed Clinical Research
    Dayton, Ohio 45419, United States
  • Allegheny Health and Wellness Pavilion
    Erie, Pennsylvania 16506, United States
  • Lockman & Lubell Pediatric Associates
    Fort Washington, Pennsylvania 19034, United States
  • Palmetto Pediatrics, PA
    North Charleston, South Carolina 29406, United States
  • Benchmark Research
    Austin, Texas 78705, United States
  • University of Texas Medical Branch
    Galveston, Texas 77555, United States
  • Tekton Research, Inc
    San Antonio, Texas 78244, United States
  • Alliance for Multispecialty Research, LLC
    Layton, Utah 84041, United States
  • Wasatch Pediatrics, Cottonwood Office
    Murray, Utah 84107, United States
  • Pediatric Care
    Provo, Utah 84604, United States
  • JBR Clinical Research
    Salt Lake City, Utah 84107, United States
  • J. Lewis Research, Inc. / Foothill Family Clinic
    Salt Lake City, Utah 84109, United States
  • J. Lewis Research, Inc./ Foothill Family Clinic South
    Salt Lake City, Utah 84121, United States
  • CopperView Medical Center
    South Jordan, Utah 84095, United States
  • J. Lewis Research, Inc. / Jordan River Family Medicine
    South Jordan, Utah 84095, United States
  • Wee Care Pediatrics
    Syracuse, Utah 84075, United States
  • Pediatric Associates of Charlottesville, PLC (Private Pediatric Practice)
    Charlottesville, Virginia 22902, United States
  • Pediatric Research of Charlottesville, LLC
    Charlottesville, Virginia 22902, United States
09

References and documents

Study documents

PDFs hosted by the registry, ClinicalTrials.gov.

Individual participant data

Plan to share: Yes — Pfizer will provide access to individual de-identified participant data and related study documents (e.g. protocol, Statistical Analysis Plan (SAP), Clinical Study Report (CSR)) upon request from qualified researchers, and subject to certain criteria, conditions, and exceptions. Further details on Pfizer's data sharing criteria and process for requesting access can be found at: https://www.pfizer.com/science/clinical_trials/trial_data_and_results/data_requests.

Data sharing details ↗ · www.pfizer.com

10

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Ran from Dec 2020 to primary completion in Apr 2022, 16 months.

Results were first posted in Apr 2023, 1 year after primary completion.

Of 81 industry-sponsored phase 3 interventional studies under Pneumococcal Infections, half reached primary completion within 12 months of starting (the median), counting those still running; a quarter within 9 and three quarters within 23. This study's 16 months is above that.

Counting every sponsor, half of 82 studies reached it within 13 months; a quarter within 9 and three quarters within 23.

How these figures are worked out, and which studies are left out of them.

Registered
Nov 18, 2020
First posted
Nov 24, 2020
StartActual
Dec 4, 2020
Primary completionActual
Apr 6, 2022
CompletionActual
Apr 6, 2022
Results first posted
Apr 26, 2023
Last update
Jan 22, 2024
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Jan 22, 2024, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
11

Registry details

Key details

Study ID
NCT04642079
Lead sponsor
Pfizer
Responsible party
Sponsor
First posted
Nov 24, 2020
Start date
Dec 4, 2020
Primary completion
Apr 6, 2022
Completion
Apr 6, 2022
Results posted
Apr 26, 2023
Last update
Jan 22, 2024

Study contacts

Pfizer CT.gov Call Center
study director · Pfizer

Oversight

Data monitoring committee
Yes
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Jan 2024. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Pneumococcal 20-Valent Conjugate Vaccine

Start the discussion